Trials / Withdrawn
WithdrawnNCT01093170
A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Mark Kleinman · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, open-label, dose-escalating Phase Ia study performed at a single center designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of intravitreous administration of RNA-144101 in patients with geographic atrophy (GA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RNA-144101 | Intravitreous administration of RNA-144101 |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2010-03-25
- Last updated
- 2018-01-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01093170. Inclusion in this directory is not an endorsement.